Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol

Abstract

Regardless of whether previous PHiD-CV vaccination was given with or without PP, induction of immunological memory and persistence of PHiD-CV's impact on carriage was seen until at least 28 months post-booster vaccination. Our study results therefore suggest that the lower immune responses after primary and booster vaccination with PP are of transient nature.

Effect of antipyretic analgesics on immune responses to vaccination

“…Children in the acetaminophen group in the 2009 study were compared to controls after the groups received a booster dose of 10-valent pneumococcal capsular polysaccharide non-typeable Hemophilus influenzae conjugate vaccine at 40 to 48 months of age. 35 The group who received acetaminophen prophylaxis had lower titers prior to the boost, but both groups had similar robust increase in titers following the boost. The blunted response observed with the primary immunization was not persistent, suggesting that there was no adverse effect on memory B cells.…”

Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)

“…Some groups of children were not included in the analyses of pooled solicited and unsolicited AE data but were assessed separately (Supplementary Table 4): those who received three catch-up doses in the second year of life or catch-up above 24 months of age in studies 013 [11], 042 [12], 046 [13], and 062 [14], and additional dose groups from studies 042 [12] and 046 [13]. Other safety results that were considered separately were those from FinIP study 043, in which safety reporting was based on spontaneous reporting only [5], and those in populations at higher risk for pneumococcal infection: HIV-infected and HIV-exposed uninfected children in study 034 (submitted manuscript).…”

“…Catch-up groups not included in the analyses of pooled safety data were children in study 062 who received a 2+1 catch-up schedule in the second year of life [14], children in study 013 who received one dose above 2 years of age [11], and children in studies 042 and 046, who received two doses above 2 years of age [12,13] (Supplementary Table 4). …”

“…The results of open controlled studies 042 and 046 were described in full previously [12,13]. As summarized in Supplementary Table 4, in study 042, 220 children previously primed and boosted (3+1 schedule) with PHiD-CV received one PHiD-CV dose in their fourth year of life to assess immunological memory [12].…”

Next Generation Pneumococcal Conjugate Vaccines Efficacy and Effectiveness in Different Regions of the World

“…ПКВ10 в многочисленных исследованиях [19,33,37,38,51,64] демонстрировала нестабильность в сниже-нии серотипспецифического носительства вакциналь-ных серотипов в разные возрастные периоды. В срав-нительном исследовании влияния на носительство ПКВ10 и ПКВ7 [33] показан сходный эффект для обе-их вакцин: снижение носительства 7 общих серотипов, отсутствие значимого эффекта по 3 дополнительным серотипам ПКВ10 (1, 5, 7F -в целом редко встречающи-еся в носительстве серотипы), нарастание носительства серотипа 19А и отсутствие различий между вакцинами в плане влияния на носительство нетипируемой гемо-фильной палочки.…”